BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21316228)

  • 1. Discovery of a potent, orally bioavailable pyrimidine VLA-4 antagonist effective in a sheep asthma model.
    Semko CM; Chen L; Dressen DB; Dreyer ML; Dunn W; Farouz FS; Freedman SB; Holsztynska EJ; Jefferies M; Konradi AW; Liao A; Lugar J; Mutter L; Pleiss MA; Quinn KP; Thompson T; Thorsett ED; Vandevert C; Xu YZ; Yednock TA
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1741-3. PubMed ID: 21316228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3',5'-dichloro-isonicotinoyl) amino]-(l)-phenylalanine (MK-0617), a highly potent and orally active VLA-4 antagonist.
    Venkatraman S; Lebsack AD; Alves K; Gardner MF; James J; Lingham RB; Maniar S; Mumford RA; Si Q; Stock N; Treonze KM; Wang B; Zunic J; Munoz B
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5803-6. PubMed ID: 19713111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist.
    Muro F; Iimura S; Yoneda Y; Chiba J; Watanabe T; Setoguchi M; Iigou Y; Takayama G; Yokoyama M; Takashi T; Nakayama A; Machinaga N
    Bioorg Med Chem; 2008 Dec; 16(23):9991-10000. PubMed ID: 18952443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyridone derivatives as potent, orally bioavailable VLA-4 integrin antagonists.
    Witherington J; Blaney EL; Bordas V; Elliott RL; Gaiba A; Garton N; Green PM; Naylor A; Smith DG; Spalding DJ; Takle AK; Ward RW
    Bioorg Med Chem Lett; 2006 Nov; 16(21):5538-41. PubMed ID: 16931004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioisosteric replacement of anilide with benzoxazole: potent and orally bioavailable antagonists of VLA-4.
    Lin LS; Lanza TJ; Castonguay LA; Kamenecka T; McCauley E; Van Riper G; Egger LA; Mumford RA; Tong X; MacCoss M; Schmidt JA; Hagmann WK
    Bioorg Med Chem Lett; 2004 May; 14(9):2331-4. PubMed ID: 15081035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identified a morpholinyl-4-piperidinylacetic acid derivative as a potent oral active VLA-4 antagonist.
    Chiba J; Machinaga N; Takashi T; Ejima A; Takayama G; Yokoyama M; Nakayama A; Baldwin JJ; McDonald E; Moriarty KJ; Sarko CR; Saionz KW; Swanson R; Hussain Z; Wong A
    Bioorg Med Chem Lett; 2005 Jan; 15(1):41-5. PubMed ID: 15582407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arylsulfonamide pyrimidines as VLA-4 antagonists.
    Xu YZ; Konradi AW; Bard F; Dappen M; Dofiles L; Dreyer M; Gallager I; Garrido C; Krimm M; Liao Z; Messersmith E; Mutter L; Pleiss MA; Samant B; Semko CM; Smith J; Stappenbeck F; Stupi B; Vandervert C; Welch B; Wipke B; Yednock T
    Bioorg Med Chem Lett; 2013 May; 23(10):3070-4. PubMed ID: 23562062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid.
    Setoguchi M; Iimura S; Sugimoto Y; Yoneda Y; Chiba J; Watanabe T; Muro F; Iigo Y; Takayama G; Yokoyama M; Taira T; Aonuma M; Takashi T; Nakayama A; Machinaga N
    Bioorg Med Chem; 2013 Jan; 21(1):42-61. PubMed ID: 23218775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists.
    Chiba J; Iimura S; Yoneda Y; Watanabe T; Muro F; Tsubokawa M; Iigou Y; Satoh A; Takayama G; Yokoyama M; Takashi T; Nakayama A; Machinaga N
    Bioorg Med Chem; 2007 Feb; 15(4):1679-93. PubMed ID: 17194595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of trans-4-[1-[[7-fluoro-2-(1-methyl-3-indolyl)-6-benzoxazolyl]acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid as a potent, orally active VLA-4 antagonist.
    Setoguchi M; Iimura S; Sugimoto Y; Yoneda Y; Chiba J; Watanabe T; Muro F; Iigo Y; Takayama G; Yokoyama M; Taira T; Aonuma M; Takashi T; Nakayama A; Machinaga N
    Bioorg Med Chem; 2012 Feb; 20(3):1201-12. PubMed ID: 22261021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-(pyrimidin-4-yl) and N-(pyridin-2-yl) phenylalanine derivatives as VLA-4 integrin antagonists.
    Porter JR; Archibald SC; Brown JA; Childs K; Critchley D; Head JC; Hutchinson B; Parton TA; Robinson MK; Shock A; Warrellow GJ; Zomaya A
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1595-8. PubMed ID: 12039570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of eosinophilia in vivo by a small molecule inhibitor of very late antigen (VLA)-4.
    Okigami H; Takeshita K; Tajimi M; Komura H; Albers M; Lehmann TE; Rölle T; Bacon KB
    Eur J Pharmacol; 2007 Mar; 559(2-3):202-9. PubMed ID: 17234179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of potential integrin VLA-4 antagonists using pharmacophore modeling, virtual screening and molecular docking studies.
    Thangapandian S; John S; Sakkiah S; Lee KW
    Chem Biol Drug Des; 2011 Aug; 78(2):289-300. PubMed ID: 21507205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The discovery of acylated beta-amino acids as potent and orally bioavailable VLA-4 antagonists.
    Lin LS; Kopka IE; Mumford RA; Magriotis PA; Lanza T; Durette PL; Kamenecka T; Young DN; de Laszlo SE; McCauley E; Riper GV; Kidambi U; Egger LA; Tong X; Lyons K; Vincent S; Stearns R; Colletti A; Teffera Y; Fenyk-Melody J; Schmidt JA; MacCoss M; Hagmann WK
    Bioorg Med Chem Lett; 2002 Feb; 12(4):611-4. PubMed ID: 11844683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-Tetrahydrofuroyl-(L)-phenylalanine derivatives as potent VLA-4 antagonists.
    Yang GX; Chang LL; Truong Q; Doherty GA; Magriotis PA; de Laszlo SE; Li B; MacCoss M; Kidambi U; Egger LA; McCauley E; Van Riper G; Mumford RA; Schmidt JA; Hagmann WK
    Bioorg Med Chem Lett; 2002 Jun; 12(11):1497-500. PubMed ID: 12031328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-(Pyrrolidinyl)methoxybenzoic acid derivatives as a potent, orally active VLA-4 antagonist.
    Chiba J; Iimura S; Yoneda Y; Sugimoto Y; Horiuchi T; Muro F; Ochiai Y; Ogasawara T; Tsubokawa M; Iigou Y; Takayama G; Taira T; Takata Y; Yokoyama M; Takashi T; Nakayama A; Machinaga N
    Chem Pharm Bull (Tokyo); 2006 Nov; 54(11):1515-29. PubMed ID: 17077548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imidazopyridines as VLA-4 integrin antagonists.
    Phillips DJ; Davenport RJ; Demaude TA; Galleway FP; Jones MW; Knerr L; Perry BG; Ratcliffe AJ
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4146-9. PubMed ID: 18539454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of N-acyl 4-(5-pyrimidine-2,4-dionyl)phenylalanine derivatives and their orally active prodrug esters as dual-acting alpha4-beta1 and alpha4-beta7 receptor antagonists.
    Sidduri A; Tilley JW; Lou J; Tare N; Cavallo G; Frank K; Pamidimukkala A; Choi DS; Gerber L; Railkar A; Renzetti L
    Bioorg Med Chem Lett; 2013 Feb; 23(4):1026-31. PubMed ID: 23312474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of trans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid: an orally active, selective very late antigen-4 antagonist.
    Muro F; Iimura S; Sugimoto Y; Yoneda Y; Chiba J; Watanabe T; Setoguchi M; Iigou Y; Matsumoto K; Satoh A; Takayama G; Taira T; Yokoyama M; Takashi T; Nakayama A; Machinaga N
    J Med Chem; 2009 Dec; 52(24):7974-92. PubMed ID: 19891440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The identification and optimization of orally efficacious, small molecule VLA-4 antagonists.
    Huryn DM; Konradi AW; Ashwell S; Freedman SB; Lombardo LJ; Pleiss MA; Thorsett ED; Yednock T; Kennedy JD
    Curr Top Med Chem; 2004; 4(14):1473-84. PubMed ID: 15544538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.